Z09 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Encntr for f/u exam aft trtmt for cond oth than malig neoplm. The 2022 edition of ICD-10-CM Z09 became effective on October 1, 2021.
The ICD-10-CM code Z09 might also be used to specify conditions or terms like attends hypertension monitoring, chiropody follow-up, chronic disease - follow-up assessment, follow-up , follow-up 1 day , follow-up 1 month, etc. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.
BILLABLE POA Exempt | ICD-10 from 2011 - 2016 Z09 is a billable ICD code used to specify a diagnosis of encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm. A 'billable code' is detailed enough to be used to specify a medical diagnosis. POA Indicators on CMS form 4010A are as follows:
Oct 01, 2021 · Z09 is a valid billable ICD-10 diagnosis code for Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm . It is found in the 2022 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2021 - Sep 30, 2022 . POA Exempt.
Z09 is a billable diagnosis code used to specify a medical diagnosis of encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm.
FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)
The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code Z09:
Z09 is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.
Z09. Billable codes are sufficient justification for admission to an acute care hospital when used a principal diagnosis. The Center for Medicare & Medicaid Services (CMS) requires medical coders to indicate whether or not a condition was present at the time of admission, in order to properly assign MS-DRG codes.
This is the official approximate match mapping between ICD9 and ICD10, as provided by the General Equivalency mapping crosswalk. This means that while there is no exact mapping between this ICD10 code Z09 and a single ICD9 code, V67.9 is an approximate match for comparison and conversion purposes.
Z09 is a billable ICD code used to specify a diagnosis of encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm. A 'billable code' is detailed enough to be used to specify a medical diagnosis.
Use Additional Code note means a second code must be used in conjunction with this code. Codes with this note are Etiology codes and must be followed by a Manifestation code or codes.
Z09 is a valid billable ICD-10 diagnosis code for Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm . It is found in the 2021 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2020 - Sep 30, 2021 .
Z09 is exempt from POA reporting ( Present On Admission).
Z codes are for use in any healthcare setting. Z codes may be used as either a first-listed (principal diagnosis code in the inpatient setting) or secondary code, depending on the circumstances of the encounter. Certain Z codes may only be used as first-listed or principal diagnosis.
Z09 is a billable ICD code used to specify a diagnosis of encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm.